首页> 美国卫生研究院文献>other >In Vitro Optimization of EtNBS-PDT against Hypoxic Tumor Environments with a Tiered High-Content 3D Model Optical Screening Platform
【2h】

In Vitro Optimization of EtNBS-PDT against Hypoxic Tumor Environments with a Tiered High-Content 3D Model Optical Screening Platform

机译:具有分层高含量3D模型光学屏蔽平台对耐血管肿瘤环境的体外优化eTNBS-PDT

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hypoxia and acidosis are widely recognized as major contributors to the development of treatment resistant cancer. For patients with disseminated metastatic lesions, such as most women with ovarian cancer (OvCa), the progression to treatment resistant disease is almost always fatal. Numerous therapeutic approaches have been developed to eliminate treatment resistant carcinoma, including novel biologic, chemo, radiation, and photodynamic therapy (PDT) regimens. Recently, PDT using the cationic photosensitizer EtNBS was found to be highly effective against therapeutically unresponsive hypoxic and acidic OvCa cellular populations in vitro. To optimize this treatment regimen, we developed a tiered, high-content, image-based screening approach utilizing a biologically relevant OvCa 3D culture model to investigate a small library of side-chain modified EtNBS derivatives. The uptake, localization, and photocytotoxicity of these compounds on both the cellular and nodular levels were observed to be largely mediated by their respective ethyl side chain chemical alterations. In particular, EtNBS and its hydroxyl-terminated derivative (EtNBS-OH) were found to have similar pharmacological parameters, such as their nodular localization patterns and uptake kinetics. Interestingly, these two molecules were found to induce dramatically different therapeutic outcomes: EtNBS was found to be more effective in killing the hypoxic, nodule core cells with superior selectivity, while EtNBS-OH was observed to trigger widespread structural degradation of nodules. This breakdown of the tumor architecture can improve the therapeutic outcome and is known to synergistically enhance the antitumor effects of front-line chemotherapeutic regimens. These results, which would not have been predicted or observed using traditional monolayer or in vivo animal screening techniques, demonstrate the powerful capabilities of 3D in vitro screening approaches for the selection and optimization of therapeutic agents for the targeted destruction of specific cellular subpopulations.
机译:缺氧和酸中毒被广泛认为是耐药性癌症发展的主要因素。对于具有转移性转移病灶的患者,例如大多数患有卵巢癌(OvCa)的妇女,进展为耐药性疾病几乎总是致命的。已经开发出许多治疗方法来消除对治疗有抗性的癌症,包括新颖的生物,化学,放射和光动力疗法(PDT)方案。最近,发现使用阳离子光敏剂EtNBS的PDT在体外对治疗性无反应的低氧和酸性OvCa细胞群体非常有效。为了优化此治疗方案,我们开发了一种基于生物学相关的OvCa 3D培养模型的分层,高含量,基于图像的筛选方法,以研究侧链修饰的EtNBS衍生物的小型文库。观察到这些化合物在细胞和结节水平上的摄取,定位和光细胞毒性主要是由它们各自的乙基侧链化学变化介导的。特别是,发现EtNBS及其羟基封端的衍生物(EtNBS-OH)具有相似的药理参数,例如它们的结节定位模式和吸收动力学。有趣的是,发现这两种分子诱导了截然不同的治疗结果:发现EtNBS可以更有效地杀死低氧结节性核心细胞,而观察到EtNBS-OH会引发结节的广泛结构降解。肿瘤结构的这种破坏可以改善治疗效果,并且已知可以协同增强一线化疗方案的抗肿瘤作用。这些结果,使用传统的单层或体内动物筛选技术无法预测或观察到,证明了3D体外筛选方法对于针对特定细胞亚群进行靶向破坏的治疗剂的选择和优化的强大功能。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号